CGRP Forum is an expert resource for clinicians and healthcare professionals working with migraine patients. All patients should discuss their medication with their healthcare professional. Unless otherwise indicated, opinions expressed in the CGRP Education and Research Forum are those of the contributors. Although every effort is made to ensure accuracy and avoid mistakes, no liability on the part of the CGRP Forum, the editors or the editorial board is accepted for the consequences of any misleading or inaccurate information.
Editorial Policy
Trials
- Atogepant (AGN-241689)
- Erenumab (AMG 334)
- Galcanezumab (LY2951742)
- Fremanezumab (TEV-48125)
- Eptinezumab (ALD403)
- Rimegepant (BHV-3000)
- Ubrogepant (MK-1602)
Meeting Reports
- Migraine Trust International Symposium 2020
- 14th European Headache Federation Congress
- 62nd Annual Meeting of the American Headache Society
- 6th Congress of the European Academy of Neurology
- American Academy of Neurology 2020
- World Congress of Neurology 2019
- IHC 2019
- American Headache Society (AHS) 61st Annual Scientific Meeting
- 5th Congress of the European Academy of Neurology
- 13th European Headache Federation Congress
- American Academy of Neurology Annual Meeting 2019
- 12th European Headache Federation Congress
- 17th Biennial Migraine Trust International Symposium
- American Headache Society (AHS) 60th Annual Scientific Meeting
- 4th Congress of the European Academy of Neurology
- American Academy of Neurology (AAN) Congress
- 11th European Headache Federation Congress
- 18th Congress of the International Headache Society
- American Headache Society Annual Scientific Meeting
- 3rd Congress of the European Academy of Neurology
- American Academy of Neurology Annual Meeting
- Scottsdale Headache Symposium
- The European Headache and Migraine Trust International Congress (EHMTIC)